We believe

Impel Pharmaceuticals is the first company to attempt to harness the benefits of delivery to the upper nasal space to improve the therapeutic potential of CNS therapies.

Unlike traditional nasal delivery systems, such as pumps, that predominantly deliver medicine to the lower nasal cavity and suffer from high variability and low overall absorption, our therapies are designed to achieve rapid absorption with consistent and predictable doses.2

liquid POD device diagram

The upper nasal space vasculature is more permeable compared to the lower nasal cavity that is less accommodating to delivered drug absorption. These advantages allow for better consistency in dosing and absorption of drugs, as well as the potential for improved efficacy and faster time to onset of action – meaning patients may stand to achieve fast and lasting symptomatic relief.3

References

1 Zachary N. Warnken et al. Journal of Drug Delivery Science and Technology. Volume 35, October 2016, Pages 213-222
2 Impel Data on File.
3 Impel Data on File.